Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A hoosier oncology group study

E. Eklund, M. E. Miller, R. Ansari, W. B. Fisher, Lawrence Einhorn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Fifty-one patients with advanced non-small-cell lung cancer were treated on a Hoosier Oncology Group protocol with an aggressive, high-dose cisplatin combination chemotherapy regimen. All patients had a Karnofsky performance status of 80% or higher and had no prior chemotherapy. The drug regimen consisted of cisplatin 30 mg/m2 days one through five, etoposide 40 mg/m2 days one through five, and vinblastine 5 mg/m2 day one. Therapy was given every three weeks for a total of three courses. Forty-five patients were evaluable for response and an objective response was seen in 15 patients (33%) with only one complete responder. The median duration of response was 16.5 weeks. The median survival for the entire group was 29.0 weeks. Toxicity was moderately severe with two treatment-related deaths (4%). Despite an aggressive chemotherapy regimen in a favorable patient population, there was no obvious evidence of a major therapeutic value.

Original languageEnglish (US)
Pages (from-to)412-415
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume14
Issue number5
StatePublished - 1991

Fingerprint

Vinblastine
Etoposide
Non-Small Cell Lung Carcinoma
Cisplatin
Karnofsky Performance Status
Drug Therapy
Combination Drug Therapy
Therapeutics
Survival
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A hoosier oncology group study. / Eklund, E.; Miller, M. E.; Ansari, R.; Fisher, W. B.; Einhorn, Lawrence.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 14, No. 5, 1991, p. 412-415.

Research output: Contribution to journalArticle

@article{ad5640e127404b3abbbac762b2856786,
title = "Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A hoosier oncology group study",
abstract = "Fifty-one patients with advanced non-small-cell lung cancer were treated on a Hoosier Oncology Group protocol with an aggressive, high-dose cisplatin combination chemotherapy regimen. All patients had a Karnofsky performance status of 80{\%} or higher and had no prior chemotherapy. The drug regimen consisted of cisplatin 30 mg/m2 days one through five, etoposide 40 mg/m2 days one through five, and vinblastine 5 mg/m2 day one. Therapy was given every three weeks for a total of three courses. Forty-five patients were evaluable for response and an objective response was seen in 15 patients (33{\%}) with only one complete responder. The median duration of response was 16.5 weeks. The median survival for the entire group was 29.0 weeks. Toxicity was moderately severe with two treatment-related deaths (4{\%}). Despite an aggressive chemotherapy regimen in a favorable patient population, there was no obvious evidence of a major therapeutic value.",
author = "E. Eklund and Miller, {M. E.} and R. Ansari and Fisher, {W. B.} and Lawrence Einhorn",
year = "1991",
language = "English (US)",
volume = "14",
pages = "412--415",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Phase II trial of high-dose cisplatin plus etoposide plus vinblastine in non-small-cell lung cancer. A hoosier oncology group study

AU - Eklund, E.

AU - Miller, M. E.

AU - Ansari, R.

AU - Fisher, W. B.

AU - Einhorn, Lawrence

PY - 1991

Y1 - 1991

N2 - Fifty-one patients with advanced non-small-cell lung cancer were treated on a Hoosier Oncology Group protocol with an aggressive, high-dose cisplatin combination chemotherapy regimen. All patients had a Karnofsky performance status of 80% or higher and had no prior chemotherapy. The drug regimen consisted of cisplatin 30 mg/m2 days one through five, etoposide 40 mg/m2 days one through five, and vinblastine 5 mg/m2 day one. Therapy was given every three weeks for a total of three courses. Forty-five patients were evaluable for response and an objective response was seen in 15 patients (33%) with only one complete responder. The median duration of response was 16.5 weeks. The median survival for the entire group was 29.0 weeks. Toxicity was moderately severe with two treatment-related deaths (4%). Despite an aggressive chemotherapy regimen in a favorable patient population, there was no obvious evidence of a major therapeutic value.

AB - Fifty-one patients with advanced non-small-cell lung cancer were treated on a Hoosier Oncology Group protocol with an aggressive, high-dose cisplatin combination chemotherapy regimen. All patients had a Karnofsky performance status of 80% or higher and had no prior chemotherapy. The drug regimen consisted of cisplatin 30 mg/m2 days one through five, etoposide 40 mg/m2 days one through five, and vinblastine 5 mg/m2 day one. Therapy was given every three weeks for a total of three courses. Forty-five patients were evaluable for response and an objective response was seen in 15 patients (33%) with only one complete responder. The median duration of response was 16.5 weeks. The median survival for the entire group was 29.0 weeks. Toxicity was moderately severe with two treatment-related deaths (4%). Despite an aggressive chemotherapy regimen in a favorable patient population, there was no obvious evidence of a major therapeutic value.

UR - http://www.scopus.com/inward/record.url?scp=0025952445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025952445&partnerID=8YFLogxK

M3 - Article

C2 - 1659175

AN - SCOPUS:0025952445

VL - 14

SP - 412

EP - 415

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 5

ER -